Important Notice for Intellia Therapeutics, Inc. (NTLA) Shareholders:
New York, April 10, 2025 – The Gross Law Firm, a leading national shareholder rights law firm, issues the following notice to all persons who purchased shares of Intellia Therapeutics, Inc. (NASDAQ: NTLA) during the class period between February 25, 2021 and October 28, 2021.
If you are a shareholder who suffered a substantial loss, you may be entitled to participate as a lead plaintiff in a securities class action lawsuit against Intellia Therapeutics, Inc. The Gross Law Firm encourages you to contact the firm as soon as possible to discuss your legal rights and potential remedies.
Class Period and Eligibility:
The class period for this lawsuit is from February 25, 2021 through October 28, 2021. During this period, Intellia Therapeutics, Inc. made materially false and misleading statements regarding the company’s business, operations, and compliance policies.
Allegations:
The lawsuit alleges that Intellia Therapeutics, Inc. made false and misleading statements and failed to disclose material information about the company’s business, operations, and compliance policies. Specifically, the company failed to disclose that:
- There were significant issues with the company’s gene-editing technology;
- The company’s clinical trials were experiencing safety concerns and regulatory issues;
- The company’s financial statements were inaccurate;
As a result of these false statements and omissions, Intellia Therapeutics, Inc. stock traded at artificially inflated prices during the class period.
Potential Impact on Shareholders:
If you purchased shares of Intellia Therapeutics, Inc. during the class period and suffered a loss, you may be able to recover your losses as a lead plaintiff in the securities class action lawsuit. The Gross Law Firm is committed to ensuring that shareholders receive the compensation they are entitled to.
Impact on the World:
The potential impact of this lawsuit on the world goes beyond just Intellia Therapeutics, Inc. shareholders. This case highlights the importance of transparency and accuracy in corporate disclosures. Companies that fail to provide accurate information to their investors can face significant consequences, including financial losses for shareholders and damage to their reputations.
Conclusion:
If you purchased shares of Intellia Therapeutics, Inc. during the class period and believe you may have suffered a loss as a result of the company’s false and misleading statements, we encourage you to contact The Gross Law Firm as soon as possible. The firm is dedicated to fighting for the rights of shareholders and ensuring that companies are held accountable for their actions. Together, we can make a difference.
For more information, please contact The Gross Law Firm toll-free at 888-223-7114 or email [email protected]. You can also find us on Facebook, LinkedIn, and Twitter.
About The Gross Law Firm: The Gross Law Firm is a national shareholder rights law firm that represents purchasers in securities fraud, antitrust, and consumer class action lawsuits. The firm seeks to recover damages on behalf of and protect the interests of its clients, who may include pension funds, institutional investors, endowments, and individuals.
The Gross Law Firm represents clients throughout the world and is committed to obtaining the best possible recovery for its clients. The firm’s attorneys have extensive experience in prosecuting securities fraud and other class action lawsuits and have recovered billions of dollars for their clients.
